Therapeutic Hypothesis: TDP-43 and Alpha-Synuclein Pathologies in the Amygdala
Overview
The co-occurrence of TDP-43 and [alpha-synuclein](/proteins/alpha-synuclein) pathologies in the amygdala represents a significant pathological intersection in neurodegenerative diseases. This hypothesis posits that these proteinopathies often represent downstream or secondary effects in brains with advanced Alzheimer's disease pathology rather than independent primary disease processes [1](https://doi.org/10.1038/s41582-023-00789-1). Understanding this relationship is crucial for developing targeted therapeutic interventions and accurate diagnostic frameworks. [@amygdala]
Mechanistic Model
Mermaid diagram (expand to render)
Evidence Assessment
Confidence Level: Moderate
The co-occurrence of TDP-43 and alpha-synuclein pathologies in the amygdala is supported by multiple postmortem studies, but the causal relationship remains uncertain. The evidence suggests these proteinopathies are frequently comorbid rather than causally linked.
Evidence Type Breakdown
| Type | Evidence |
|------|----------|
| Genetic | C9orf72 expansions cause both TDP-43 and alpha-synuclein pathology [@c9orf72]; TBK1 mutations link ALS/FTD with synucleinopathies [@tbk1] |
| Clinical | Amygdala co-pathology correlates with more severe neuropsychiatric symptoms [@amygdala2023] |
| Neuropathological | SEA-AD data shows 40-60% of AD brains have amygdala TDP-43 [@late2024]; Alpha-synuclein in 30-50% of TDP-43 cases [@alphasynuclein] |
| Experimental | Cross-seeding demonstrated in cell and animal models [@synucleinb2024] |
| Computational | Protein interaction network analysis predicts TDP-43/α-syn synergy |
Key Supporting Studies
Nelson et al. (2023) — SEA-AD characterization of amygdala TDP-43 prevalence
Robinson et al. (2018) — Mixed pathologies account for most dementia cases
Yushkevich et al. (2022) — Quantitative analysis of protein co-occurrence
Zhang et al. (2024) — TDP-43 and α-synuclein cross-seeding mechanisms
Josephs et al. (2023) — LATE-NC staging and clinical correlationsKey Challenges and Contradictions
- Some cases show TDP-43 pathology without alpha-synuclein and vice versa
- Regional specificity of amygdala vs. other brain regions unclear
- Primary vs. secondary pathology distinction difficult in clinical practice
Testability Score: 8/10
The hypothesis can be tested through:
- Longitudinal imaging of TDP-43 and α-syn progression
- CSF biomarker analysis for both proteins
- Postmortem correlation with clinical staging
Therapeutic Potential Score: 7/10
Common therapeutic targets: autophagy enhancement, RNA processing modifiers, protein clearance
Pathological Context
TDP-43 Proteinopathy
TAR DNA-binding protein 43 (TDP-43) is a nuclear protein involved in RNA metabolism, splicing, and transport. In neurodegenerative diseases, TDP-43 accumulates in the cytoplasm as insoluble inclusions, a pathology observed in: [@tdp2019]
- Amyotrophic Lateral Sclerosis (ALS): Approximately 95% of ALS cases feature TDP-43 inclusions [2](https://doi.org/10.1016/j.neurobiolaging.2019.03.001)
- Frontotemporal Dementia (FTD): TDP-43 is the primary pathology in ~45% of FTD cases [3](https://doi.org/10.1007/s00401-021-01308-3)
- Alzheimer's Disease: TDP-43 inclusions found in 20-50% of AD brains, often co-localizing with [tau](/proteins/tau) pathology [4](https://doi.org/10.1007/s00401-022-02416-3)
- Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE): Recently characterized as a distinct TDP-43 proteinopathy [5](https://doi.org/10.1093/brain/awz099)
Alpha-Synuclein Pathology
Alpha-synuclein is a presynaptic protein involved in neurotransmitter release. Its misfolding and aggregation into Lewy bodies characterizes: [@tdp]
- Parkinson's Disease (PD): Lewy bodies primarily in substantia nigra
- Dementia with Lewy Bodies (DLB): Diffuse cortical Lewy body distribution
- Multiple System Atrophy (MSA): Oligodendrocytic cytoplasmic inclusions (GCIs)
Key Proteins and Genes
| Entity | Role | Wiki Link |
|--------|------|------------|
| [TDP-43](/proteins/tdp-43-protein) | RNA-binding protein, forms cytoplasmic inclusions | [TDP-43 Protein](/proteins/tdp-43-protein) |
| [Alpha-synuclein](/proteins/alpha-synuclein) | Synuclein family, forms Lewy bodies | [Alpha-Synuclein](/proteins/alpha-synuclein) |
| [TARDBP](/genes/tardbp) (TDP-43 gene) | Encodes TDP-43 protein | [TARDBP Gene](/genes/tardbp) |
| [SNCA](/genes/snca) (α-syn gene) | Encodes alpha-synuclein | [SNCA Gene](/genes/snca) |
| [C9orf72](/genes/c9orf72) | Hexanucleotide expansion causes both pathologies | [C9orf72 Gene](/genes/c9orf72) |
| [TBK1](/genes/tbk1) | Kinase mutations link ALS/FTD with synucleinopathies | [TBK1 Gene](/genes/tbk1) |
| [OPTN](/genes/optn) | Autophagy receptor in TDP-43 pathology | [OPTN Gene](/genes/optn) |
| [mTOR](/proteins/mtor) | Dysregulated in TDP-43 proteinopathy | [mTOR Protein](/proteins/mtor) |
| [FUS](/genes/fus) | RNA-binding protein, ALS/FTD mutations | [FUS Gene](/genes/fus) |
| [TIA1](/genes/tia1) | Stress granule component, TDP-43 pathology | [TIA1 Gene](/genes/tia1) |
| [p62](/genes/sqstm1) | Autophagy receptor, aggregates in TDP-43 | [SQSTM1 Gene](/genes/sqstm1) |
| [UBQLN2](/genes/ubqln2) | Ubiquitin-binding protein in inclusions | [UBQLN2 Gene](/genes/ubqln2) |
The Amygdala as a Pathological Hub
The amygdala is particularly vulnerable to multiple proteinopathies due to: [@tdpa]
High neuronal connectivity: Extensive inputs from cortical and subcortical regions
Emotional memory functions: Dense serotonergic and noradrenergic innervation
Early tau pathology: One of the first regions showing neurofibrillary tangles in AD
Neuroinflammation: Activated [microglia](/cell-types/microglia-neuroinflammation) and complement proteinsCo-Pathology in the Amygdala
Research from the Seattle-Alzheimer's Disease Brain Cell Atlas (SEA-AD) has revealed [1](https://doi.org/10.1038/s41582-023-00789-1): [@latenc]
- Co-existence patterns: TDP-43 and alpha-synuclein often appear in adjacent neuronal populations [6](https://doi.org/10.1093/brain/awab421)
- Temporal progression: [Amyloid-beta](/proteins/amyloid-beta) deposition precedes tau, which may facilitate TDP-43 and alpha-synuclein aggregation
- Clinical correlations: Amygdala co-pathology correlates with more severe neuropsychiatric symptoms
Experimental Approaches
Single-cell transcriptomics: Understanding cell-type specific vulnerability
Proteomic analysis: Mapping protein interaction networks in affected neurons
Longitudinal imaging: Tracking pathology progression in living patients
iPSC models: Patient-derived neurons to study TDP-43/α-syn interactions
Biomarker development: CSF and plasma markers for both proteinsTherapeutic Implications
Targeting Downstream Effects
Modulating protein clearance: Enhancing [autophagy](/entities/autophagy) and ubiquitin-proteasome systems [@autophagy]
Reducing propagation: Blocking interneuronal spread of pathological proteins
Neuroinflammation: Targeting microglial activation to prevent secondary pathologyDiagnostic Considerations
- Biomarker development: CSF and plasma markers for TDP-43 and alpha-synuclein
- PET ligands: Emerging tracers to detect co-pathology in vivo
- Clinical staging: Incorporating amygdala pathology into disease progression models
- [Pathologic Synergy Between Protein Species](/hypotheses/hyp_885074) — discusses cross-seeding mechanisms
- [Tau Hyperphosphorylation in AD](/hypotheses/hyp_87091) — upstream trigger for TDP-43/α-syn co-pathology
- [Prion-like Protein Propagation](/hypotheses/hyp_332160) — spreading mechanisms
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
- [Autophagy Dysfunction](/entities/autophagy)
- [Neuroinflammation](/cell-types/microglia-neuroinflammation)
References
[Nelson et al., Amygdala pathology in neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00789-1)
[TDP-43 pathology in ALS (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.001)
[TDP-43 in FTD (2021)](https://doi.org/10.1007/s00401-021-01308-3)
[TDP-43 pathology in Alzheimer's disease (2022)](https://doi.org/10.1007/s00401-022-02416-3)
[LATE-NC: Limbic-predominant age-related TDP-43 encephalopathy](https://doi.org/10.1093/brain/awz099)
[Alpha-synuclein and TDP-43 co-pathology in the amygdala](https://doi.org/10.1093/brain/awab421)
[Co-morbid proteinopathies in Alzheimer's disease](https://doi.org/10.1007/s00401-021-02276-3)
[TDP-43 pathology in AD (2024)](https://doi.org/10.1007/s00401-024-02648-1)
[Alpha-synuclein seeding in TDP-43 proteinopathy (2024)](https://doi.org/10.1007/s00401-024-02679-w)
[Amygdala co-pathology patterns (2023)](https://doi.org/10.1093/brain/awad333)
[LATE-NC prevalence and staging (2024)](https://doi.org/10.1007/s00401-024-02655-4)
[C9orf72 hexanucleotide expansion in ALS/FTD](https://doi.org/10.1016/S1474-4422(21)00294-2)
[TBK1 mutations in ALS/FTD](https://doi.org/10.1038/nn.4000)See Also
- [SEA-AD Project](/projects/sea-ad)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [FTD](/diseases/frontotemporal-lobar-degeneration)
References
[Nelson et al., Amygdala pathology in neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00789-1)
[TDP-43 pathology in ALS (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.001)
[TDP-43 in FTD (2021)](https://doi.org/10.1007/s00401-021-01308-3)
[TDP-43 pathology in Alzheimer's disease (2022)](https://doi.org/10.1007/s00401-022-02416-3)
[LATE-NC: Limbic-predominant age-related TDP-43 encephalopathy](https://doi.org/10.1093/brain/awz099)
[Alpha-synuclein and TDP-43 co-pathology in the amygdala](https://doi.org/10.1093/brain/awab421)
[Co-morbid proteinopathies in Alzheimer's disease](https://doi.org/10.1007/s00401-021-02276-3)
[TDP-43 pathology in AD (2024)](https://doi.org/10.1007/s00401-024-02648-1)
[Alpha-synuclein seeding in TDP-43 proteinopathy (2024)](https://doi.org/10.1007/s00401-024-02679-w)
[Amygdala co-pathology patterns (2023)](https://doi.org/10.1093/brain/awad333)
[LATE-NC prevalence and staging (2024)](https://doi.org/10.1007/s00401-024-02655-4)
[C9orf72 hexanucleotide expansion in ALS/FTD](https://doi.org/10.1016/S1474-4422(21)00294-2)
[TBK1 mutations in ALS/FTD](https://doi.org/10.1038/nn.4000)
[OPTN mutations in neurodegenerative disease (2016)](https://doi.org/10.1093/brain/aww223)
[mTOR dysregulation in TDP-43 proteinopathy (2023)](https://doi.org/10.1007/s00401-023-02598-8)
[Autophagy impairment in TDP-43 proteinopathy (2024)](https://doi.org/10.1080/15548627.2024.2342655)
[Amygdala involvement in Lewy body disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)
[TDP-43 and tau co-pathology in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[LATE-NC clinical correlates (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)
[Cross-seeding mechanisms in proteinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/39890123/)Evidence Rubric
Confidence Level: Moderate
The co-occurrence of TDP-43 and alpha-synuclein pathologies in the amygdala is supported by extensive postmortem studies, with SEA-AD data demonstrating:
- 40-60% of AD brains have amygdala TDP-43 pathology
- 30-50% of TDP-43 cases show alpha-synuclein co-pathology
- The causal relationship remains under investigation
The evidence supports a comorbidity model rather than direct causal linkage in most cases.
Evidence Type Breakdown
| Type | Evidence |
|------|----------|
| Genetic | C9orf72 expansions cause both TDP-43 and alpha-synuclein pathology; TBK1 mutations link ALS/FTD with synucleinopathies |
| Clinical | Amygdala co-pathology correlates with more severe neuropsychiatric symptoms, faster progression |
| Neuropathological | SEA-AD data shows 40-60% of AD brains have amygdala TDP-43; Alpha-synuclein in 30-50% of TDP-43 cases |
| Experimental | Cross-seeding demonstrated in cell and animal models; Protein interaction networks predict synergy |
| Biomarker | CSF and plasma markers for both proteins under development |
Testability Score: 8/10
The hypothesis can be tested through:
- Longitudinal imaging of TDP-43 and α-syn progression using emerging PET ligands
- CSF and plasma biomarker analysis for both protein species
- Postmortem correlation with clinical staging and cognitive outcomes
- iPSC-derived neuron models of co-pathology
- Cross-seeding experiments in model systems
Therapeutic Potential Score: 8/10
Common therapeutic targets across both pathologies:
- Autophagy enhancement to improve protein clearance
- RNA processing modifiers for TDP-43 dysfunction
- Protein aggregation inhibitors for both species
- Neuroinflammation targeting to prevent secondary pathology
- Combination approaches addressing both proteins simultaneously
Key Evidence Gaps
Primary vs. secondary distinction: Determining which cases represent primary vs. secondary proteinopathies
Regional specificity: Understanding why amygdala is particularly vulnerable
Temporal sequence: Determining which pathology appears first in progression
Mechanistic links: Identifying molecular intermediates between pathologies
Biomarker validation: Developing validated in vivo markers for both proteinsMolecular Mechanisms of Co-Pathology
Cross-Seeding Mechanisms
The interaction between TDP-43 and alpha-synuclein pathologies involves multiple molecular mechanisms:
Direct protein interaction: TDP-43 and α-syn can directly bind and influence each other's aggregation
Shared degradation pathways: Both proteins are cleared through autophagy-lysosome and ubiquitin-proteasome systems
Stress response convergence: Cellular stress pathways affect both proteins similarly
Membrane trafficking disruption: Both pathologies affect endosomal and lysosomal functionAmygdala Vulnerability Factors
The amygdala shows particular vulnerability to co-pathology due to:
High neuronal connectivity: Extensive inputs from cortical and subcortical regions
Emotional memory functions: Dense serotonergic and noradrenergic innervation
Early tau pathology: One of the first regions showing neurofibrillary tangles in AD
Neuroinflammation susceptibility: Enhanced microglial activation and complement deposition
Metabolic factors: High energy demands and mitochondrial density
Protein turnover challenges: High synaptic activity increases misfolding riskTherapeutic Implications Flowchart
Mermaid diagram (expand to render)
Clinical Implications
Diagnostic Considerations
The presence of amygdala co-pathology has important clinical implications:
Disease progression: Co-pathology associated with faster cognitive decline
Neuropsychiatric symptoms: Increased anxiety, depression, and agitation
Treatment response: Some medications may be less effective with mixed pathology
Prognosis: Earlier placement, more rapid functional declineBiomarker Development
Current biomarker development focuses on:
CSF markers: Measuring TDP-43 and α-syn in cerebrospinal fluid
Blood tests: Emerging plasma and exosome-based assays
Imaging: Development of PET ligands for both protein species
Multimodal approaches: Combining biomarkers for improved accuracyClinical Trial Implications
Understanding co-pathology is critical for clinical trial design:
Patient stratification: Identifying mixed pathology cases
Endpoint selection: Different endpoints for pure vs. mixed pathology
Combination therapies: Developing treatments targeting multiple proteins
Biomarker validation: Using co-pathology biomarkers for patient selection
Disease Progression Model
Stage 1 - Preclinical (LATE-NC)
| Feature | Details |
|---------|---------|
| Timeline | 5-10 years before cognitive symptoms |
| Pathology | TDP-43 confined to amygdala |
| Clinical | No measurable cognitive impairment |
| Biomarkers | CSF TDP-43 elevated, p-tau normal |
| Imaging | MRI shows subtle amygdalar atrophy |
| Therapeutic Window | Primary prevention |
Stage 2 - Mild Cognitive Impairment
| Feature | Details |
|---------|---------|
| Timeline | 2-5 years of progressive symptoms |
| Pathology | TDP-43 spreads to hippocampus |
| Clinical | Memory complaints, preserved daily function |
| Biomarkers | CSF TDP-43 high, NFL elevated |
| Imaging | Hippocampal atrophy on MRI |
| Therapeutic Window | Disease modification |
Stage 3 - Dementia (LATE-Dementia)
| Feature | Details |
|---------|---------|
| Timeline | Progressive cognitive decline |
| Pathology | TDP-43 widespread in limbic system |
| Clinical | Memory loss, neuropsychiatric symptoms |
| Biomarkers | Multiple CSF abnormalities |
| Imaging | Diffuse cortical atrophy |
| Therapeutic Window | Symptomatic management |
Genetic Susceptibility Factors
| Gene | Variant | Effect on Co-Pathology | Risk |
|------|---------|------------------------|------|
| C9orf72 | Hexanucleotide expansion | Causes both TDP-43 and α-syn pathology | High |
| TBK1 | Loss-of-function mutations | Links ALS/FTD with synucleinopathies | Moderate |
| GRN | Null mutations | TDP-43 haploinsufficiency | Moderate |
| MAPT | H1 haplotype | Modifies tau, affects TDP-43 progression | Low |
| SNCA | Multiplication | Primary α-syn pathology | High |
| GBA | Loss-of-function | Impairs lysosomal clearance | Moderate |
Sex Differences in Co-Pathology
Research indicates significant sex differences in the presentation of TDP-43/α-syn co-pathology:
Female-Predominant Factors:
- Higher prevalence of LATE-NC in females[@josephs2023]
- More rapid progression once cognitive symptoms emerge
- Greater neuropsychiatric burden
Male-Predominant Factors:
- More frequent C9orf72-related cases
- Earlier onset in some genetic forms
- More prominent motor features with co-pathology
Clinical Implications:
- Diagnostic criteria may need sex-specific refinement
- Treatment response may differ by sex
- Biomarker thresholds may require adjustment
Brain Region Vulnerability Mapping
Primary Affected Regions
| Region | Primary Pathology | Secondary Changes |
|--------|-------------------|-------------------|
| Amygdala | TDP-43 inclusions, Lewy bodies | Neuronal loss, gliosis |
| Hippocampus | TDP-43 in CA1/subiculum | Synaptic loss, memory circuits |
| Entorhinal cortex | TDP-43 in layer II | Projection neuron loss |
| Temporal neocortex | Variable TDP-43 | Corticocortical disconnection |
Connectivity-Based Spread
The pattern of co-pathology follows connectivity networks:
Perirhinal pathway: Amygdala → Entorhinal cortex → Hippocampus
Basolateral circuit: Amygdala → Prefrontal cortex → Orbital frontal
Papez circuit: Mammillary bodies → Anterior thalamus → CingulateTherapeutic Targeting by Region
| Region | Delivery Strategy | Challenge |
|--------|-------------------|-----------|
| Amygdala | Stereotactic injection | Limited diffusion |
| Hippocampus | Intrathecal | CSF distribution |
| Cortex | Systemic | BBB penetration |
| Brainstem | Intrathecal/IV | Limited retrograde transport |
Experimental Approaches
In Vitro Models
Primary Neuron Cultures: Amygdala neuron cultures to study co-pathology
iPSC-Derived Neurons: Patient-derived cells with C9orf72/TBKI mutations
Co-culture Systems: TDP-43 and α-syn expressing cells together
Organotypic Brain Slices: Maintain regional architectureIn Vivo Models
Transgenic Mice: TDP-43 and α-syn co-expression models
Viral Vectors: AAV-mediated expression in amygdala
Patient Xenografts: Human neurons in mouse brain
Optogenetic Models: Light-induced pathologyHuman Studies
Postmortem Atlas Studies: SEA-AD, Banner, ROS
Biomarker Cohorts: BioFINDER, ADNI, MARKers
Imaging Studies: PET ligands under development
Genetic Studies: GWAS for co-pathology modifiers
Future Directions
Unanswered Questions
What determines which protein pathology develops first?
Can we prevent secondary proteinopathy after primary diagnosis?
What molecular pathways link different proteinopathies?
How do we model co-pathology in experimental systems?Emerging Research Areas
Single-cell proteomics: Cell-type specific pathology patterns
Spatial transcriptomics: Regional vulnerability mechanisms
Cryo-EM structures: Strain differences in co-pathology
Systems biology: Network approaches to protein interactionsTherapeutic Development Priorities
Common pathway targeting: Focus on shared mechanisms
Combination approaches: Dual-targeting strategies
Biomarker-driven trials: Enriched patient populations
Stage-specific interventions: Different approaches by disease stageReferences
[Nelson et al., Amygdala pathology in neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00789-1)
[TDP-43 pathology in ALS (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.001)
[TDP-43 in FTD (2021)](https://doi.org/10.1007/s00401-021-01308-3)
[TDP-43 pathology in Alzheimer's disease (2022)](https://doi.org/10.1007/s00401-022-02416-3)
[LATE-NC: Limbic-predominant age-related TDP-43 encephalopathy](https://doi.org/10.1093/brain/awz099)
[Alpha-synuclein and TDP-43 co-pathology in the amygdala](https://doi.org/10.1093/brain/awab421)
[Co-morbid proteinopathies in Alzheimer's disease](https://doi.org/10.1007/s00401-021-02276-3)
[TDP-43 pathology in AD (2024)](https://doi.org/10.1007/s00401-024-02648-1)
[Alpha-synuclein seeding in TDP-43 proteinopathy (2024)](https://doi.org/10.1007/s00401-024-02679-w)
[Amygdala co-pathology patterns (2023)](https://doi.org/10.1093/brain/awad333)
[LATE-NC prevalence and staging (2024)](https://doi.org/10.1007/s00401-024-02655-4)
[C9orf72 hexanucleotide expansion in ALS/FTD](https://doi.org/10.1016/S1474-4422(21)00294-2)
[TBK1 mutations in ALS/FTD](https://doi.org/10.1038/nn.4000)
[OPTN mutations in neurodegenerative disease (2016)](https://doi.org/10.1093/brain/aww223)
[mTOR dysregulation in TDP-43 proteinopathy (2023)](https://doi.org/10.1007/s00401-023-02598-8)
[Autophagy impairment in TDP-43 proteinopathy (2024)](https://doi.org/10.1080/15548627.2024.2342655)